These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Bayer pharma chief sees no big acquisitions in near ... and potentially the rise of novel legal theories applied to less traditional products. Here are some of the top cases to watch in 2025.

Bayer recently submitted an application to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for this third indication for darolutamide in addition ...

( MENAFN - GlobeNewsWire - Nasdaq) Dublin, Jan. 20, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Bayer AG 2024" report has been added to ResearchAndMarkets.com's offering.

Bayer Aktiengesellschaft (ETR:BAYN – Get Free Report) shares were up 0.4% on Wednesday . The stock traded as high as €19.99 ($20.61) and last traded at €19.79 ($20.40). Approximately 3,072,022 shares ...

At the same time, the value of our pipeline is growing by accelerating breakthrough innovations," said Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer’s ...